It is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. Ever since our establishment in the 2004, we are known as a leading organization engaged in offering Sennoside A. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. This compound inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. We offer Sennoside A at market leading prices to clients.